医薬品受託製造市場：サービス別、エンドユーザー別-2025-2030年の世界予測

医薬品受託製造市場の2023年の市場規模は1,140億7,000万米ドルで、2024年には1,236億4,000万米ドルに達すると予測され、CAGR 8.46％で成長し、2030年には2,014億6,000万米ドルに達すると予測されています。

医薬品受託製造市場は、製薬会社による医薬品製造や包装を含む製造サービスのアウトソーシングを、専門の第三者機関に委託するものです。この分野は、拡張性のある生産能力、コスト効率、専門知識の強化に対する製薬業界のニーズが高まっているため、極めて重要です。受託製造は主に、生物製剤、原薬（API）、固形・半固形製剤、注射剤に適用され、バイオ製薬会社、ジェネリック医薬品メーカー、小規模バイオテクノロジー企業など、複数のエンドユーザーの生産ニーズに対応しています。市場成長の原動力となっているのは、ジェネリック医薬品需要の高まり、生物製剤製造の複雑化、規制要件の厳格化、製薬業界におけるコスト抑制の重視などです。新興国市場と継続的な研究開発投資は潜在的な成長機会を提供し、そこでは強力なパートナーシップを築き、品質コンプライアンスに注力することが決定的となります。戦略的パートナーシップや合併を進め、市場シェアを獲得するための能力を強化しようという動向も高まっています。しかし課題としては、激しい競争、規制遵守の複雑さ、知的財産の盗難やデータ漏洩のリスクなどがあります。また、高度な製造施設の設置や技術的な適応性を維持するためのコストが高いという制約もあります。連続製造、個別化医療製造、先進パッケージング・ソリューションなどの分野における技術革新は極めて重要です。これらの技術革新は、より高い効率を保証するだけでなく、顧客固有の要件によりよく対応します。さらに、人工知能と機械学習を統合することで、生産プロセスを合理化し、サプライチェーン管理を改善することができます。ビジネスの成長のためには、競争力を維持するために、堅牢な世界サプライチェーンネットワークの構築とデジタルトランスフォーメーションの推進に注力することが不可欠です。市場の性質は協調的であり、成功のためには品質保証と顧客の透明性が重視されるようになっています。このような取り組みは、世界の医薬品製造のダイナミックな需要と複雑化に効果的に対応する上で極めて重要です。

市場力学：急速に進化する医薬品受託製造市場の主要市場インサイトを公開

医薬品受託製造市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • ジェネリック医薬品と生物学的治療薬に対する需要の高まり
  • 医薬品研究開発・製造への投資の増加
  • CMO数の増加と先進製造技術への投資の増加
• 市場抑制要因
  • シリアライゼーション規格のイントロダクション
• 市場機会
  • 特殊医薬品への注目の高まりと魅力的な核医学分野
  • 標的治療のための細胞・遺伝子治療への需要の高まり
• 市場の課題
  • 各国間の貿易政策の変化

ポーターの5つの力：医薬品受託製造市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：医薬品受託製造市場における外部からの影響の把握

外部マクロ環境要因は、医薬品受託製造市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析医薬品受託製造市場における競合情勢の把握

医薬品受託製造市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス医薬品受託製造市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、医薬品受託製造市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨医薬品受託製造市場における成功への道筋を描く

医薬品受託製造市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品上市、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • ジェネリック医薬品と生物学的療法の需要増加
    • 医薬品研究開発と製造への投資の増加
    • CMO数の増加と先進製造技術への投資の増加
  • 抑制要因
    • シリアル化標準のイントロダクション
  • 機会
    • 専門医薬品と魅力的な核医学分野への注目が高まる
    • 標的治療のための細胞・遺伝子治療の需要増加
  • 課題
    • 国家間の貿易政策の変化
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 医薬品受託製造市場：サービス別

• バイオ医薬品製造サービス
  • 生物製剤API製造サービス
  • バイオロジクスFDF製造サービス
• 医薬品開発サービス
• 医薬品製造サービス
  • 医薬品API製造
    • カプセル製造サービス
    • 経口液剤製造サービス
    • 非経口/注射剤製造サービス
    • タブレット製造サービス
  • 医薬品FDF製造
• 二次包装サービス

第7章 医薬品受託製造市場：エンドユーザー別

• 大手製薬会社
• ジェネリック医薬品会社
• 中小規模の製薬会社

第8章 南北アメリカの医薬品受託製造市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の医薬品受託製造市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの医薬品受託製造市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • マイヴァ・ファーマ、ホスールの新施設で製造を拡大するため1億1,900万米ドルの投資を確保
  • キューネ・ホールディングAGがBCパートナーズからアエノバ・グループを買収
  • トニックス・ファーマシューティカルズ、アルマックと提携してトンミヤのデュアルソース商業生産を開始
  • アドベント・インターナショナルがコハンス・ライフサイエンスとスベン・ファーマを合併
  • オーロビンド・ファーマ、メルク・シャープ・アンド・ドームと提携し、生物製剤の契約製造市場に参入
• 戦略分析と提言

企業一覧

• AbbVie, Inc.
• Aenova Group GmbH
• Almac Group
• Amgen Inc.
• Baxter International Inc.
• Biozoc Inc.
• Boehringer Ingelheim International GmbH
• Cambrex Corporation
• Catalent, Inc.
• Curia Global, Inc.
• Danaher Corporation
• Dr. Reddy's Laboratories Ltd.
• Elkos Group
• Evonik Industries AG
• Famar Group
• Fareva Group
• Jubilant Pharma Limited
• Kryptochem Medicament Pvt. Ltd.
• Lonza Group
• Midas Pharma GmbH
• Mitsubishi Tanabe Pharma Corporation
• Nipro Group
• Novartis AG
• Pfizer Inc.
• Pidolma Healthcare
• PYRAMID Laboratories, Inc.
• Recipharm AB
• Serum Institute of India Ltd.
• Siegfried Holding AG
• Sycon Healthcare
• Thermo Fisher Scientific Inc.
• Vetter Pharma-Fertigung GmbH & Co. KG

LIST OF FIGURES

• FIGURE 1. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
• FIGURE 2. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET DYNAMICS
• TABLE 7. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS API MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS FDF MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULE MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ORAL LIQUID MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PARENTERAL/INJECTABLE MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TABLET MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL FDF MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SECONDARY PACKAGING SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIG PHARMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GENERIC PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SMALL & MID-SIZE PHARMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 44. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 45. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 46. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 47. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 70. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 71. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 72. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 73. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 74. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. INDIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 76. INDIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 77. INDIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 78. INDIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 79. INDIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. MALAYSIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. PHILIPPINES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. SINGAPORE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. TAIWAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. THAILAND PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. VIETNAM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 131. DENMARK PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. EGYPT PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. FINLAND PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 151. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 156. ISRAEL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 161. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 162. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 163. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 164. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 165. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 166. NETHERLANDS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 171. NIGERIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 176. NORWAY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 181. POLAND PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 182. POLAND PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 183. POLAND PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 184. POLAND PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 185. POLAND PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 186. QATAR PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 187. QATAR PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 188. QATAR PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 189. QATAR PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 190. QATAR PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 191. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 196. SAUDI ARABIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 206. SPAIN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 211. SWEDEN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 216. SWITZERLAND PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 221. TURKEY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 236. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 237. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

The Pharmaceutical Contract Manufacturing Market was valued at USD 114.07 billion in 2023, expected to reach USD 123.64 billion in 2024, and is projected to grow at a CAGR of 8.46%, to USD 201.46 billion by 2030.

The pharmaceutical contract manufacturing market involves outsourcing manufacturing services, including drug production and packaging, by pharmaceutical companies to specialized third-party organizations. This sector is vital due to the pharmaceutical industry's growing need for scalable production capabilities, cost efficiency, and expertise enhancement. Contract manufacturing primarily finds application in biologics, active pharmaceutical ingredients (APIs), solid and semi-solid dosage forms, and injectables, addressing the production needs across multiple end-users such as biopharmaceutical companies, generic drug manufacturers, and small-scale biotech firms. Market growth is driven by the rising demand for generic drugs, the increasing complexity of manufacturing biologics, stringent regulatory requirements, and the emphasis on cost containment within the pharmaceutical industry. Emerging markets and continuous R&D investment provide potential growth opportunities, where developing strong partnerships and focusing on quality compliance can be decisive. There's a growing trend towards strategic partnerships and mergers, enhancing capabilities to capture market share. However, challenges include intense competition, regulatory compliance complexities, and the risk of intellectual property theft or data breaches. Other limitations involve the high cost of setting up advanced manufacturing facilities and maintaining technological adaptability. Innovation in areas like continuous manufacturing, personalized medicine production, and advanced packaging solutions is critical. These innovations not only ensure higher efficiency but also better address client-specific requirements. Furthermore, integrating artificial intelligence and machine learning can streamline production processes and improve supply chain management. For business growth, it's essential to focus on building robust global supply chain networks and advancing digital transformation to remain competitive. The market's nature is collaborative, with a growing emphasis on quality assurance and client transparency to succeed. Such efforts are crucial in responding effectively to the dynamic demands and growing complexities of pharmaceutical production globally.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pharmaceutical Contract Manufacturing Market

The Pharmaceutical Contract Manufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising Demand for Generics and Biological Therapies
  • Increasing Investments in Pharmaceutical R&D and Manufacturing
  • Increasing Number of CMOs and Rising Investments in Advanced Manufacturing Technologies
• Market Restraints
  • Introduction of Serialization Standards
• Market Opportunities
  • Increasing Focus on Specialty Drugs and Attractive Nuclear Medicine Sector
  • Growing Demand for Cell and Gene Therapies for Targeted Treatment
• Market Challenges
  • Changing Trade Policies Between Countries

Porter's Five Forces: A Strategic Tool for Navigating the Pharmaceutical Contract Manufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pharmaceutical Contract Manufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pharmaceutical Contract Manufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pharmaceutical Contract Manufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pharmaceutical Contract Manufacturing Market

A detailed market share analysis in the Pharmaceutical Contract Manufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pharmaceutical Contract Manufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pharmaceutical Contract Manufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Pharmaceutical Contract Manufacturing Market

A strategic analysis of the Pharmaceutical Contract Manufacturing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Pharmaceutical Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Aenova Group GmbH, Almac Group, Amgen Inc., Baxter International Inc., Biozoc Inc., Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Curia Global, Inc., Danaher Corporation, Dr. Reddy's Laboratories Ltd., Elkos Group, Evonik Industries AG, Famar Group, Fareva Group, Jubilant Pharma Limited, Kryptochem Medicament Pvt. Ltd., Lonza Group, Midas Pharma GmbH, Mitsubishi Tanabe Pharma Corporation, Nipro Group, Novartis AG, Pfizer Inc., Pidolma Healthcare, PYRAMID Laboratories, Inc., Recipharm AB, Serum Institute of India Ltd., Siegfried Holding AG, Sycon Healthcare, Thermo Fisher Scientific Inc., and Vetter Pharma-Fertigung GmbH & Co. KG.

Market Segmentation & Coverage

This research report categorizes the Pharmaceutical Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Service, market is studied across Biologics Manufacturing Services, Drug Development Services, Pharmaceutical Manufacturing Services, and Secondary Packaging Services. The Biologics Manufacturing Services is further studied across Biologics API Manufacturing Services and Biologics FDF Manufacturing Services. The Pharmaceutical Manufacturing Services is further studied across Pharmaceutical API Manufacturing and Pharmaceutical FDF Manufacturing. The Pharmaceutical API Manufacturing is further studied across Capsule Manufacturing Services, Oral Liquid Manufacturing Services, Parenteral/Injectable Manufacturing Services, and Tablet Manufacturing Services.
• Based on End-User, market is studied across Big Pharma, Generic Pharmaceutical Companies, and Small & Mid-Size Pharma.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising Demand for Generics and Biological Therapies
    • 5.1.1.2. Increasing Investments in Pharmaceutical R&D and Manufacturing
    • 5.1.1.3. Increasing Number of CMOs and Rising Investments in Advanced Manufacturing Technologies
  • 5.1.2. Restraints
    • 5.1.2.1. Introduction of Serialization Standards
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing Focus on Specialty Drugs and Attractive Nuclear Medicine Sector
    • 5.1.3.2. Growing Demand for Cell and Gene Therapies for Targeted Treatment
  • 5.1.4. Challenges
    • 5.1.4.1. Changing Trade Policies Between Countries
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Pharmaceutical Contract Manufacturing Market, by Service

• 6.1. Introduction
• 6.2. Biologics Manufacturing Services
  • 6.2.1. Biologics API Manufacturing Services
  • 6.2.2. Biologics FDF Manufacturing Services
• 6.3. Drug Development Services
• 6.4. Pharmaceutical Manufacturing Services
  • 6.4.1. Pharmaceutical API Manufacturing
    • 6.4.1.1. Capsule Manufacturing Services
    • 6.4.1.2. Oral Liquid Manufacturing Services
    • 6.4.1.3. Parenteral/Injectable Manufacturing Services
    • 6.4.1.4. Tablet Manufacturing Services
  • 6.4.2. Pharmaceutical FDF Manufacturing
• 6.5. Secondary Packaging Services

7. Pharmaceutical Contract Manufacturing Market, by End-User

• 7.1. Introduction
• 7.2. Big Pharma
• 7.3. Generic Pharmaceutical Companies
• 7.4. Small & Mid-Size Pharma

8. Americas Pharmaceutical Contract Manufacturing Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Pharmaceutical Contract Manufacturing Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Pharmaceutical Contract Manufacturing Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
  • 11.3.1. Maiva Pharma secures USD 119 million investment to expand manufacturing with new Hosur facility
  • 11.3.2. Kuhne Holding AG acquires Aenova Group from BC Partners
  • 11.3.3. Tonix Pharmaceuticals partners with Almac for dual-source commercial production of Tonmya
  • 11.3.4. Advent International merges Cohance Lifescience with Suven Pharma
  • 11.3.5. Aurobindo Pharma partners with Merck Sharp and Dohme to enter biologics contract manufacturing market
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie, Inc.
• 2. Aenova Group GmbH
• 3. Almac Group
• 4. Amgen Inc.
• 5. Baxter International Inc.
• 6. Biozoc Inc.
• 7. Boehringer Ingelheim International GmbH
• 8. Cambrex Corporation
• 9. Catalent, Inc.
• 10. Curia Global, Inc.
• 11. Danaher Corporation
• 12. Dr. Reddy's Laboratories Ltd.
• 13. Elkos Group
• 14. Evonik Industries AG
• 15. Famar Group
• 16. Fareva Group
• 17. Jubilant Pharma Limited
• 18. Kryptochem Medicament Pvt. Ltd.
• 19. Lonza Group
• 20. Midas Pharma GmbH
• 21. Mitsubishi Tanabe Pharma Corporation
• 22. Nipro Group
• 23. Novartis AG
• 24. Pfizer Inc.
• 25. Pidolma Healthcare
• 26. PYRAMID Laboratories, Inc.
• 27. Recipharm AB
• 28. Serum Institute of India Ltd.
• 29. Siegfried Holding AG
• 30. Sycon Healthcare
• 31. Thermo Fisher Scientific Inc.
• 32. Vetter Pharma-Fertigung GmbH & Co. KG